SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 51.85%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.31 per share when it actually produced a loss of $0.27, delivering a surprise of 12.90%.Over the last four quarters, t ...

EXHIBIT 99.1 Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results November 6, 2024 07:00 a.m. ET EDEN PRAIRIE, Minn. – Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary • Total Revenue of $33.2 million, an increase of 19% year-over-year • Total Revenue excluding Sur ...

Surmodics, Inc. (SRDX) received the FDA's 510(k) clearance for its Pounce XL Thrombectomy System yesterday. Following the regulatory clearance, the Pounce Thrombectomy Platform can now likely be used to remove clots from peripheral arteries ranging from 2mm to 10 mm in diameter. Surmodics expects to initiate a limited market release for the Pounce XL Thrombectomy System in the first half of 2025, with commercialization planned following the completion of the limited market release. The latest FDA approval f ...

Shares of SurModics (SRDX) have been struggling lately and have lost 5.1% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case fo ...

A downtrend has been apparent in SurModics (SRDX) lately with too much selling pressure. The stock has declined 5.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spo ...

SurModics (SRDX) has been on a downward spiral lately with significant selling pressure. After declining 6.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock i ...

For the quarter ended June 2024, SurModics (SRDX) reported revenue of $30.34 million, down 42.2% over the same period last year. EPS came in at -$0.27, compared to $0.52 in the year-ago quarter. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Here is how SurModics performed in the just reported quarter in terms of the m ...

This quarterly report represents an earnings surprise of 12.90%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.36 per share when it actually produced earnings of $0.07, delivering a surprise of 119.44%. SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarter ...

Other long-term liabilities consisted of the following: | --- | --- | --- | --- | --- | |-------------------------------------------------------------|-------|-----------------------------|-------|------------------------------| | (In thousands) \nDeferred consideration (1) | $ | June 30, 2024 \n1,653 | $ | September 30, 2023 \n1,629 | | Unrecognized tax benefits (2) | | 2,951 | | 3,332 | | Operating lease liabilities, less current portion | | 2,915 | | 2,974 | | Other | | 266 | | 125 | | Other long-term li ...

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results Third Quarter Fiscal 2024 Financial Summary "Our team's focus and execution in the third quarter enabled us to deliver total revenue results consistent with the expectations shared on our most recent earnings call, benefiting from strength across multiple areas of our business," said Gary Maharaj, President and CEO of Surmodics, Inc. "Specifically, we saw strong contributions from growth in both Medical Device product revenue – driven pri ...